Arrowhead Pharmaceuticals (ARWR) Intangibles (2010 - 2026)

Arrowhead Pharmaceuticals' Intangibles history runs 17 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• Quarterly Intangibles fell 22.05% year-over-year to $6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.0 million (down 22.05% YoY) and the FY2025 annual result came in at $6.9 million, down 19.87% from the prior year.
• Intangibles was $6.0 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $6.4 million in the prior quarter.
• Across five years, Intangibles topped out at $12.8 million in Q1 2022 and bottomed at $6.0 million in Q1 2026.
• A 5-year average of $9.4 million and a median of $9.4 million in 2024 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles declined 11.71% — and 2026, when it declined 22.05%.
• Arrowhead Pharmaceuticals' Intangibles stood at $11.5 million in 2022, then dropped by 14.74% to $9.8 million in 2023, then fell by 17.28% to $8.1 million in 2024, then dropped by 20.9% to $6.4 million in 2025, then decreased by 6.6% to $6.0 million in 2026.
• Business Quant data shows ARWR's Intangibles at $6.0 million in Q1 2026, $6.4 million in Q4 2025, and $6.9 million in Q3 2025.